Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Uracil and its saltsF1 when sold for the treatment of cancer I DEC / 11
Urea in topical preparations in concentrations of more than 25% II SEP / 98
UrokinasePDL I DEC / 13
Ursodeoxycholic acid and its saltsF1 I SEP / 98
UstekinumabF1 I MAR / 11
Vaccines (except for - those which are part of a routine immunization program in most/all provinces and territories: Diphtheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus) I FEB / 02
Vaccines. which are part of a routine immunization program in most/all provinces and territories: Diptheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus II FEB / 02
Valaciclovir and its saltsF1 I SEP / 98
Valdecoxib and its saltsF1 I MAY / 04
Valganciclovir and its salts and derivativesF1 I MAY / 04
Valproic acid and its saltsF1 I SEP / 98
Valrubicin and its derivativesF1 I DEC / 02
Valsartan and its salts and derivativesF1 I SEP / 99
Vancomycin and its salts and derivativesF1 I SEP / 98
Vardenafil and its saltsF1 I APR / 07
Varenicline or its saltsPDL I DEC / 13
Varicella Zoster immune globulin I FEB / 02
Varicella vaccine (chicken pox) I FEB / 02
Vasopressin and its saltsF1 I SEP / 98
Vecuronium bromideF1 I SEP / 98
Vedaprofen and its salts and derivativesF1 I MAY / 00
VedolizumabPDL I MAR / 15
Vegetable tar except shampoos in concentrations of 5% or less III SEP / 98
Velaglucerase alfaPDL I DEC / 13
VelpatasvirPDL I AUG / 16
Venetoclax or its saltsPDL I NOV / 16
Venlafaxine and its saltsF1 I SEP / 98
Verapamil and its saltsF1 I SEP / 98
Veratrum album and its alkaloids and their saltsF2 I SEP / 98
Veratrum viride and its alkaloids and their saltsF2 I SEP / 98
Vernakalant or its saltsPDL I APR / 17
VidarabineF1 I SEP / 98
Vigabatrin and its salts and derivativesF1 I SEP / 98
Vilazodone or its saltsPDL I AUG / 15
VinbarbitalC2 I JUN / 02
Vinblastine and its saltsF1 I SEP / 98
Vincristine and its saltsF1 I SEP / 98
Vindesine and its saltsF1 I SEP / 98
Vinorelbine and its saltsF1 I SEP / 98
VinylbitalC2 I JUN / 02
Viomycin and its salts and derivativesF1 I SEP / 98
Virginiamycin and its salts and derivativesF2 I SEP / 98
Vitamin APDL

in oral dosage forms containing more than 10,000 International Units of Vitamin A per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 International Units of Vitamin A

I DEC / 13
Vitamin B12 with Intrinsic Factor ConcentrateF1 I SEP / 98
Vitamin DPDL

in oral dosage form containing more than 1,000 International Units of Vitamin D per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by the person of more than 1,000 International Units of Vitamin D

I DEC / 13
Vitamin KF2 except Vitamin K1 and Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less I OCT / 05
Vitamins any parenterals not otherwise included in Schedule I II SEP / 98
Vitamins in injectable form for parenteral nutrition I JAN / 03
Vorapaxar or its saltsPDL I AUG / 16
VoriconazoleF1 I FEB / 07
VorinostatF1 I MAR / 11
Vortioxetine or its saltsPDL

including but not limited to vortioxetine hydrobromide

I DEC / 14
Xanthinol nicotinateF1 I SEP / 98
Xylazine and its saltsF1 I SEP / 98
Xylometazoline and it salts in nasal preparations for pediatric use (0.05%) II SEP / 98
Xylometazoline and its salts in nasal preparations for adults (0.1%) U
Xylose II SEP / 98
Yellow Fever vaccine I FEB / 02
Yohimbine and its saltsF1 I SEP / 98
Zafirlukast and its saltsF1 I SEP / 99
Zalcitabine and its saltsF1 I SEP / 98
Zanamivir and its salts and derivativesF1 I DEC / 01
ZeranolC3 I SEP / 98
ZidovudineF1 I SEP / 98
Zinc chloride in injectable form for parenteral nutrition I JAN / 03
Zinc sulfate in injectable form for parenteral nutrition I JAN / 03
Ziprasidone and its saltsF1 I MAY / 09
Zoledronic acid and its salts and derivativesF1 I DEC / 02
Zolpidem and any salts thereofTS I JAN / 03
Zomepirac and its saltsF1 I SEP / 98
Zopiclone and its saltsF1 I SEP / 98
ZucapsaicinPDL I DEC / 13
Zuclopenthixol and its salts and derivativesF1 I SEP / 98
a - MethylthiofentanylN I JUN / 02
alpha1- proteinase inhibitor (human) I JAN / 06
p-FluorofentanylN I JUN / 02

1876 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled